```json
{
  "treatment_information": [
    {
      "treatment_type": "Monitoring",
      "specific_treatment": "Thyroid function tests",
      "start_date": "2021-01-01",  // Start of the second pregnancy monitoring
      "end_date": "2021-12-01",  // End of pregnancy monitoring
      "dosage_or_details": "Tests performed regularly during pregnancy",
      "treatment_response": "Initially showed elevation in FT3 and FT4 followed by a decline and symptom alleviation."
    }
  ],
  "treatment_timeline": [
    {
      "date": "2021-01-01",
      "event": "Patient was monitored for thyroid function tests during her second pregnancy."
    },
    {
      "date": "2021-02-01",
      "event": "At 4 weeks gestation, FT3 and FT4 were slightly above prepregnancy levels."
    },
    {
      "date": "2021-02-15",
      "event": "Between 6 and 7 weeks gestation, symptoms of anxiety, tremor, tiredness, and palpitations occurred."
    },
    {
      "date": "2021-03-01",
      "event": "At 10 weeks gestation, serum concentrations of hCG measured at 257 kU/liter; TSH became undetectable."
    },
    {
      "date": "2021-03-15",
      "event": "At 12 weeks gestation, the patient reported losing 2 kg; symptoms started to ameliorate."
    },
    {
      "date": "2021-06-01",
      "event": "At 16 weeks gestation, FT3 and FT4 declined and symptoms subsided."
    },
    {
      "date": "2021-09-01",
      "event": "Normal vaginal delivery of a healthy boy."
    },
    {
      "date": "2021-09-15",
      "event": "At 4 weeks postpartum, TSH levels were recorded."
    }
  ]
}
```